Induced pluripotent stem cells can be strategically utilized at several biological levels, as described below. [Read more…]
Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy
MILPITAS, Calif. — Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space. [Read more…]
Laverock Therapeutics founded to develop the next generation of programmable cell therapies
31st August 2022, Stevenage, UK — Laverock Therapeutics Ltd was founded to develop a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the Company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of an experienced senior management team. [Read more…]
10 International Scientists Nominated For The $100,000 Stem Cell SpaceShot Grant
Bordeaux, France / August 30th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced the nomination of 10 international scientists for the Stem Cell SpaceShot grant. Each nominee was anonymously selected based on a 1-page research project description. In early October, the 10 nominees will be interviewed by an international jury of experts in stem cell biology, gene editing and biophysics, which will determine the winner of the $100,000 Stem Cell SpaceShot Grant. [Read more…]
Overcoming major challenges in cardiac drug discovery using human induced pluripotent stem cell technology
Highlights
- The biggest opportunity for success in cardiac drug discovery and development is to make these processes more efficient and affordable, since they carry relatively higher risk of clinical trial failure compared to other disciplines.
- Human iPSC technology is increasingly utilized to develop disease models that reliably mimic the diversity of patient pathogenicity and disease severity in vitro.
- Phenotypic screening based on iPSC-derived disease models is making cardiac drug discovery more time and cost effective by enabling target-agnostic studies and increasing the translational power of early drug discovery outcomes.
- « Previous Page
- 1
- …
- 77
- 78
- 79
- 80
- 81
- …
- 201
- Next Page »